Prism Finds Funding From Japanese Government VC To Launch New Trials
This article was originally published in PharmAsia News
Executive Summary
Prism’s lead compound is already in-licensed by Eisai for cancer indications, and the startup is now looking for a partner for the compound’s fibrosis indications now that Phase I plans are in the works.